Vanguard Group Inc. Grows Stake in Privia Health Group, Inc. (NASDAQ:PRVA)

Vanguard Group Inc. boosted its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,278,334 shares of the company’s stock after purchasing an additional 274,345 shares during the quarter. Vanguard Group Inc. owned approximately 9.51% of Privia Health Group worth $259,740,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Benjamin Edwards Inc. boosted its position in shares of Privia Health Group by 44.9% in the 4th quarter. Benjamin Edwards Inc. now owns 3,239 shares of the company’s stock worth $75,000 after buying an additional 1,003 shares in the last quarter. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Privia Health Group in the fourth quarter valued at about $158,000. International Assets Investment Management LLC grew its position in shares of Privia Health Group by 2,721.7% in the fourth quarter. International Assets Investment Management LLC now owns 7,139 shares of the company’s stock valued at $164,000 after purchasing an additional 6,886 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Privia Health Group by 30.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 8,214 shares of the company’s stock worth $189,000 after purchasing an additional 1,928 shares in the last quarter. Finally, Assetmark Inc. raised its position in shares of Privia Health Group by 32.1% during the 4th quarter. Assetmark Inc. now owns 9,754 shares of the company’s stock worth $225,000 after purchasing an additional 2,370 shares during the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Insider Activity at Privia Health Group

In other Privia Health Group news, Director Adam Boehler acquired 5,306 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was bought at an average cost of $16.50 per share, for a total transaction of $87,549.00. Following the completion of the purchase, the director now directly owns 5,773,158 shares in the company, valued at $95,257,107. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Thomas A. Mccarthy bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The shares were acquired at an average cost of $16.37 per share, for a total transaction of $163,700.00. Following the acquisition, the director now owns 52,611 shares in the company, valued at approximately $861,242.07. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Adam Boehler purchased 5,306 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was bought at an average price of $16.50 per share, with a total value of $87,549.00. Following the acquisition, the director now owns 5,773,158 shares in the company, valued at $95,257,107. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 293,235 shares of company stock worth $4,745,481 and have sold 49,390 shares worth $897,700. 14.20% of the stock is currently owned by insiders.

Privia Health Group Stock Up 1.5 %

PRVA stock opened at $17.38 on Monday. The company has a market cap of $2.07 billion, a price-to-earnings ratio of 115.87, a PEG ratio of 2.72 and a beta of 0.78. The business has a fifty day simple moving average of $17.50 and a 200-day simple moving average of $19.76. Privia Health Group, Inc. has a 52 week low of $15.92 and a 52 week high of $28.23.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.03). The firm had revenue of $415.24 million for the quarter, compared to analyst estimates of $435.07 million. Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. As a group, analysts expect that Privia Health Group, Inc. will post 0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PRVA has been the subject of several recent research reports. Truist Financial dropped their price target on Privia Health Group from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, May 15th. Barclays cut their target price on shares of Privia Health Group from $22.00 to $19.00 and set an “equal weight” rating for the company in a research note on Monday, May 20th. JPMorgan Chase & Co. decreased their price target on shares of Privia Health Group from $38.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 6th. Canaccord Genuity Group cut their price objective on shares of Privia Health Group from $37.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Finally, Baird R W upgraded shares of Privia Health Group to a “strong-buy” rating in a research report on Thursday, May 30th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $24.92.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.